Fig. 7

In vivo efficacy of CTX-HSA-NPs combined with TGFβ-1 siRNA LNP. A TIR after CTX preparation and TGFβ-1 siRNA LNP treatment. B Tumor tissue treated with CTX preparation and TGFβ-1 siRNA LNP. C Growth curve of mice treated with prepared CTX and TGFβ-1 siRNA LNP. D RTV after treatment with CTX and TGFβ-1 siRNA LNP (n = 5). (To improve the clarity of RTV, the D are divided into D1, D2 and D3). D1 RTV of CTX-HSA-NPs and CTX-Tween at doses of 5 mg/kg and 10 mg/kg. D2 The RTV of TGFβ-1 siRNA LNP and CTX-HSA-NPs combined group and CTX-HSA-NPs and CTX-Tween single group. D3 RTV of CTX-HSA-NPs with different HSA/CTX ratios. (ns, P > 0.05, ^*P < 0.05, ^**P < 0.01) (n = 5)